



Overview

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is a biotechnology company developing off-the-shelf regenerative products that no longer require the injection of stem cells. Our first platform, Cell Free Therapeutics, harnesses the biological secretions of cells to create therapies that can be immediately administered following injuries or to treat acute and chronic diseases. Our second platform is the development of non-invasive, bioelectronics to stimulate the body's natural repair system to treat injuries and inflammatory diseases.

Management Team

Alan Collier

Chairman & Chief Executive Officer

Michael Mann

President

Leonard Makowka, M.D., Ph.D.

Chief Medical Officer

Don Calabria

Chief Operating Officer

Recent News

Friday, January 11, 2019 - 09:15 AM

[Endonovo Therapeutics Issues Shareholder Letter and Update](#)

Thursday, January 03, 2019 - 11:10 AM

[Endonovo Therapeutics Enters into \\$10 million Common Stock Purchase Agreement with Azure Capital](#)

Tuesday, December 18, 2018 - 09:25 AM

[Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office](#)

Thursday, December 13, 2018 - 09:20 AM

[Endonovo Expands SofPulse Commercialization](#)

Monday, December 03, 2018 - 10:00 AM

[Endonovo Therapeutics Announces Strategic Relationship with US Authentic Trading Company](#)

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

Contact Information

Endonovo Therapeutics, Inc.

6320 Canoga Ave
15th Floor
Woodland Hills, CA 91367

OTCQB: ENDV



Share Price	\$0.03
Volume	2.25m
Shares Outstanding	395,129,771
Market Cap	\$10.39m
52 Week High	\$0.07
52 Week Low	\$0.02

as of 01/23/2019